Heart Failure is a disease involving many different aspects of the human body, including
changes in metabolism, the way the body produces and uses energy. Research shows that
patients with heart failure often have a sleep disorder called sleep disordered breathing
(SDB). It has been shown that SDB is associated with poor outcomes in heart failure patients,
but the exact reason is unknown. It is likely that SDB leads to changes in metabolism and
hormone status in the body, which is especially dangerous for heart failure patients. There
is currently no treatment for SDB in heart failure patients. Recently, with Sodium glucose
co-transporter 2 (SGLT2)-Inhibitors a new drug class has been approved for the treatment of
advanced heart failure. This drug has effects on the metabolism in heart failure patients,
among several other effects. This research project has the aim to investigate if SGLT2
inhibitors can help in the treatment of SDB, as many mechanisms of the drug overlap with the
mechanisms how SDB develops. The drug has been approved by the FDA for the treatment of heart
failure. The investigators want to study the effect of the drug on SDB by using a home sleep
test called Watchpat, which has been approved to diagnose SDB.